OPTIRAY 240 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Optiray 240, and what generic alternatives are available?
Optiray 240 is a drug marketed by Liebel-flarsheim and is included in two NDAs.
The generic ingredient in OPTIRAY 240 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
Summary for OPTIRAY 240
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,047 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | OPTIRAY 240 at DailyMed |
Recent Clinical Trials for OPTIRAY 240
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Guerbet/Liebel-Flarsheim | Phase 4 |
| Duke Clinical Research Institute | Phase 4 |
| GE Healthcare | Phase 4 |
Pharmacology for OPTIRAY 240
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for OPTIRAY 240
US Patents and Regulatory Information for OPTIRAY 240
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 240 | ioversol | INJECTABLE;INJECTION | 019710-002 | Dec 30, 1988 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Liebel-flarsheim | OPTIRAY 240 | ioversol | INJECTABLE;INJECTION | 020923-001 | May 28, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIRAY 240
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Liebel-flarsheim | OPTIRAY 240 | ioversol | INJECTABLE;INJECTION | 019710-002 | Dec 30, 1988 | ⤷ Try a Trial | ⤷ Try a Trial |
| Liebel-flarsheim | OPTIRAY 240 | ioversol | INJECTABLE;INJECTION | 020923-001 | May 28, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTIRAY 240
See the table below for patents covering OPTIRAY 240 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0083964 | COMPOUNDS SUITABLE FOR X-RAY VISUALISATION METHODS | ⤷ Try a Trial |
| Australia | 552188 | ⤷ Try a Trial | |
| Canada | 1198739 | DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE) | ⤷ Try a Trial |
| Netherlands | 930067 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTIRAY 240
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0083964 | SPC/GB93/089 | United Kingdom | ⤷ Try a Trial | SPC/GB93/089: 20041015 |
| 0083964 | 93C0142 | Belgium | ⤷ Try a Trial | PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
